© 2024 MJH Life Sciences™ and Center for Biosimilars®. All rights reserved.
Dan Danielson, RPh, MS, has over 20 years of experience developing and leading pharmacy programs in the health plan and pharmacy benefit management (PBM) industry. At PrecisionValue, he leverages his experience in advising his clients. He is experienced in leading programs and projects in which he was accountable for forecasting the impact of high-cost pharmaceuticals, developing utilization management programs, and providing thought leadership to executive teams. He has deep experience with Pharmacy and Therapeutics (P&T) Committees, Medical Policy Committees and a Value Assessment Committee. As a recognized expert in value and technology assessment, Dan is sought out to advise and review budget impact and cost-effectiveness models.
Dan is a member of the Academy of Managed Care Pharmacy (AMCP) and the International Society for Pharmacoeconomics and Outcomes Research (ISPOR). He has served as a contributor to ICER’s Unsupported Price Increase draft protocol. Dan received his Bachelor of Science and Bachelor of Pharmacy degrees from Oregon State University. He received his Master of Science degree in pharmaceutical policy and economics from the University of North Carolina, Chapel Hill.
August 22, 2023
Article
Dan Danielson, RPh, MS, senior director, market access solutions, at PrecisionValue, a market access marketing firm, explains the remaining issues at play slowing down biosimilar uptake in the United States.